Mitral valve replacement with «KemCor» and «PeriCor» bioprostheses: long-term results

We present long-term performance of KemCor and PeriCor bioprostheses in mitral position. There were 231 inplantations, with mean follow-up period of 48±30 (6-124) months. Actuarial survival was 98.6±0.7% by the end of 1st year, 90±2.3% - 5th year, and in 7th year of follow-up it was 88.6±2.6%. Among the risk factors for death we found significance in patients' age (beta -1.5±0.6, р = 0.02), and prolonged post-operative adaptation period beta (0.7±0.2, р = 0.006). Ten-year freedom of structural dysfunction was 49±1% for the entire group, and93±5% for the aged patients. Ten-year freedom of thromboembolic events was 90±4%, and 10-year freedom of major bleeding events was as high as 98.5±1%. Conclusion: KemCor and PeriCor bioprostheses show good clinical and hemodynamic long-term performance in aged patients. Long-term follow-up also demonstrates that mitral valve replacement with KemCor and PeriCor in patients younger than 60 y/o bears the risks of dysfunction and reoperation.